Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Management of irAEs in Cancer Care Requires Novel Strategies Beyond Steroids
Although the emergence of immunotherapy have created additional treatment options for patients with various types of cancer, these agents are associated with significant toxicities and immune-related adverse effects.
LITESPARK-013 Data Support RP2D of Belzutifan as Standard Option in Advanced ccRCC
November 11th 2023Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.
Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC
November 11th 2023Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.
Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management
November 10th 2023Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.
Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer
November 10th 2023Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.
Enfortumab Vedotin Plus Pembrolizumab Has Potential to Alter SOC in Frontline Urothelial Cancer
The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.
Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC
November 10th 2023David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.
Treatments for Translocation RCC Require Novel Therapeutic Targets
November 10th 2023Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.
Dr Braunstein on Stem Cell Transplant Eligibility Criteria in Multiple Myeloma
November 9th 2023Marc J. Braunstein, MD, PhD, discusses the evolution of stem cell transplant eligibility criteria in patients with multiple myeloma and highlights unanswered questions about the role of autologous stem cell transplantation following quadruplet induction regimens in this population.
Dr Markman on Pragmatic Clinical Trial Designs in Ovarian Cancer
November 9th 2023Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.
Markman Underscores Unanswered Questions in Ovarian Cancer Management
November 9th 2023Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.
Data Continue to Refine Frontline BTK Inhibitor Selection in CLL
Along with the combination of venetoclax and obinutuzumab, the BTK inhibitor–based regimens of zanubrutinib monotherapy and acalabrutinib plus obinutuzumab represent the preferred options in the National Comprehensive Cancer Network Guidelines for the first-line treatment of patients with chronic lymphocytic leukemia without 17p deletions or TP53 mutations.
Dr Morris on Active Surveillance in Low- and Intermediate-Risk Patients With Prostate Cancer
November 3rd 2023David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.
